Unfractionated Heparin Market Is Expected to Rise to an Estimated Value of US$1664.4 mn in 2025

Global Unfractionated Heparin Market: Snapshot

Unfractionated heparin is a naturally occurring anticoagulant that is primarily in dialysis and heart lung machines to prevent blood clots as well as for the treatment of blood clotting disorders such as deep venous thrombosis (DVT) and pulmonary embolism. Unfractionated heparin is also highly popular owing to its immediate onset of action, simple laboratory monitoring, short half-life, ability to get reversed (protamine), and low cost.

In the past few years, the vast rise in usage of unfractionated heparin for the treatment of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) along with the massive rise in the number of surgical procedures that take unfractionated heparin as the preferred anticoagulant have spelled growth for the global unfractionated heparin market. Although unfractionated heparin is one of the most primitive forms of heparin, the narrow therapeutic window and risks associated with bleeding act as the major restraints to its uptake, thus stifling the growth prospects of the market to a certain extent. Patent expiration of majority of unfractionated heparin products has created a huge opportunity for generic and biosimilar manufacturers.

The global unfractionated heparin market was valued at US$ 955.9 mn in 2016 and is expected to rise to an estimated value of US$1664.4 mn in 2025, expanding at a CAGR of 6.4 % from 2017 to 2025.

Request to View Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=32198

Bovine-based Unfractionated Heparin to Gain Traction as Drug Bodies Propose Re-introduction in Banned Regions

Global unfractionated heparin market has been studied on the basis of two key sources, namely bovine and porcine. The porcine-based unfractionated heparin segment accounted for the dominant share in the overall market in 2016. Bovine-based unfractionated heparin was banned in the U.S. and Europe region post 1990s due to the spread of bovine spongiform encephalopathy (BSE) disease in cattle. However, the Center for Drug Evaluation and Research (CDER), U.S., has recently proposed the re-introduction of bovine-based heparin due to shortage of porcine sourced unfractionated heparin.

On the basis of distribution channel, the segment of hospital pharmacies dominates the market owing to the rising number of hospital surgeries and hospital stay. Rise in use of internet, and surge of e-commerce are expected to boost the growth of online pharmacies segment in near future.

Request to View Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32198

North America and Europe to Present Promising Growth Opportunities

The global unfractionated heparin market by geography has been studied for North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America is presently the leading contributor to the global market owing to the vast prevalence of DVT and PE in the U.S. Studies suggest that in the U.S., nearly 900,000 people are affected by DVT every year. Approximately 50% of DVT/PE patients develop long-term complications and one-third would have a recurrence within 10 years. Thus the demand for unfractionated heparin is high in the region.

Europe follows North America in terms of growth opportunities for the unfractionated heparin market. The burgeoning geriatric population on dialysis and rising incidences of coagulation disorders in the region are attributed to the high demand for unfractionated heparin in the region. Asia Pacific, Latin America, and Middle East and Africa are largely untapped regional markets and are expected to be the fastest growing markets during the forecast period. Data from the National Institute of Health Consensus depicted that the overall incidence of DVT after elective hip surgery in India is around 45% to 70%, whereas the probability of PE is approximately 20%. Growing economy, healthcare infrastructure and increasing number of surgical procedures in Asia Pacific, Latin America, and Middle East and Africa are likely to boost unfractionated heparin market in these regions.

Report Overview @ https://www.prnewswire.com/news-releases/global-unfractionated-heparin-market-is-projected-to-reach-valuation-of-us16644-million-by-2025-transparency-market-research-673350623.html

Some of the leading companies in the global unfractionated heparin market are Fresenius SE & Co. KGaA, LEO Pharma A/S, Pfizer, Inc., B. Braun Melsungen AG, Baxter International Inc., and Sagent Pharmaceuticals.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.